Loading organizations...
Sophon Capital operates as an AI angel fund, providing pre-seed and seed checks to startups that leverage artificial intelligence as a foundational element of their business model. The firm specifically targets companies where the product intrinsically improves through usage, proprietary data, feedback loops, or network effects, seeking solutions that offer 5-10x enhancements in unit economics rather than incremental gains. It employs a structured evaluation framework, analyzing potential investments across aspects like bottleneck attack, compounding insight, reliable autonomy, and embedding depth to assess their viability and defensibility.
The fund was established by Josh Arnold, who founded Sophon Capital with the specific aim of supporting companies engaged in the automation of high-stakes decision-making processes. Arnold brings significant operational and strategic experience, having co-founded Patronus AI, an ML-driven legal outcome prediction firm, and contributed to strategy work for Fortune 500 companies at Strategy&, underpinned by an analytical background from the Wharton School. His insight was recognizing the need to back AI businesses designed for inherent compounding value.
Sophon Capital primarily serves founders of early-stage AI companies, particularly those developing solutions for high-stakes judgment automation in fields such as finance, legal, risk management, and complex R&D. The firm's vision centers on identifying and nurturing AI-native businesses that build defensible positions by integrating AI not merely as a feature, but as the core engine for substantial, compounding improvements, guiding them towards significant market impact.
Sophon Capital has 1 tracked investment across 1 company. The latest tracked deal is $4.0M Seed in Mirai Labs in February 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 11, 2025 | Mirai Labs | $4.0M Seed | Mechanism Capital | Bitscale Capital, Lhava, Manifold, OAK Grove Ventures, Protagonist, Rubik Capital, Selini Capital |